Piedmont continues to deliver impressive drilling results

|

Published 14-MAR-2019 17:04 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Piedmont Lithium Ltd (ASX:PLL) could continue their strong run after the company released impressive Phase 4 drill results on Thursday morning.

These are related to 23 drill holes completed on the Piedmont Lithium Project located within the world-class Carolina Tin-Spodumene Belt in North Carolina.

The high-grade results are from the recently discovered pegmatites on the Central property and Exploration Target areas on the Core property as indicated below.

Grades in excess of 1.7% lithium

High-grade mineralization was encountered in all 23 holes drilled.

Positive drill results from the Central property continue, including the thickest high-grade intercept reported on the project to-date, being 43.2 metres at 1.73% lithium.

Management now expects to publish a maiden Mineral Resource estimate for the Central property by April 2019, a significant phase in the project’s development and quite possibly a defining moment for the company’s share price.

Phase 4 drilling continues on the Core property with the principal aim to significantly expand the 13- year project life reported in the company’s Scoping Study announced in September 2018.

Further updates to the project’s existing Mineral Resource of 16.2 million tonnes at 1.12% lithium are expected over the next several months, and these may also provide added share price momentum.

It is worth noting that the company’s shares have increased by nearly 30% from approximately 9 cents at the start of 2019 to yesterday’s closing price of 11.5 cents, representing a three month high.

This rerating has occurred under high-volume trading, including 3.5 million shares on Tuesday last week, the largest daily volume since 2017.

The following chart demonstrates that the company has broken well clear of the 12 month trend line in March.

Despite this strength, as the market was about to open a large number of sellers accounting for more than 1 million shares were building at 11.5 cents and 12 cents, perhaps signalling that some profit-taking may occur or a ‘buy the rumour, sell the fact’ scenario could unfold.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X